Trial · NCT01665092
Rapid Administration of Carnitine in sEpsis
NCT01665092, Phase 2, Completed, University of Mississippi Medical Center; results first posted 2019-06-04
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Rapid Administration of Carnitine in sEpsis. Trials, record NCT01665092. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01665092
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Rapid Administration of Carnitine in sEpsis
- NCT number
- NCT01665092
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 250 participants, actual
- Lead sponsor
- University of Mississippi Medical Center
- Conditions
- Septic Shock
- Interventions
- Levo-Carnitine, placebo
- First posted
- 2012-08-15
- Last updated
- 2019-06-04
- Results first posted
- 2019-06-04
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Delta SOFA Score | 48 hours | Sequential Organ Failure Assessment Score (0-24 range). Delta SOFA is calculated as (SOFA Score at 48 hours post enrollment minus SOFA Score at enrollment). A negative value indicates improvement in the score. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Delta SOFA Score | 48 hours | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Delta SOFA Score | Control | -1.8 | Standard Deviation 0.35 | units on a scale | |
| Delta SOFA Score | Carnitine Low | -0.34 | Standard Deviation 0.66 | units on a scale | |
| Delta SOFA Score | Carnitine Medium | -1.68 | Standard Deviation 0.61 | units on a scale | |
| Delta SOFA Score | Carnitine High | -2.15 | Standard Deviation 0.37 | units on a scale |
Source ClinicalTrials.gov
Participant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Control | 75 | |
| Overall Study | STARTED | Carnitine Low | 35 | |
| Overall Study | STARTED | Carnitine Medium | 34 | |
| Overall Study | STARTED | Carnitine High | 106 | |
| Overall Study | COMPLETED | Control | 75 | |
| Overall Study | COMPLETED | Carnitine Low | 35 | |
| Overall Study | COMPLETED | Carnitine Medium | 32 | |
| Overall Study | COMPLETED | Carnitine High | 105 | |
| Overall Study | NOT COMPLETED | Control | 0 | |
| Overall Study | NOT COMPLETED | Carnitine Low | 0 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Control | 34 | 75 |
| Total, all-cause mortality | Carnitine Low | 20 | 35 |
| Total, all-cause mortality | Carnitine Medium | 16 | 34 |
| Total, all-cause mortality | Carnitine High | 45 | 106 |
| Total, other adverse events | Control | 0 | 75 |
| Total, other adverse events | Carnitine Low | 0 | 35 |
| Total, other adverse events | Carnitine Medium | 0 | 34 |
| Total, other adverse events | Carnitine High | 0 | 106 |
| Total, serious adverse events | Control | 0 | 75 |
| Total, serious adverse events | Carnitine Low | 0 | 35 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 30646314 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01665092
GET https://conductscience.org/api/trials/v1/NCT01665092/registered